Peripheral nervous system in gyrate atrophy of the choroid and retina with hyperornithinemia

Neurology

Volumn 59, Issue 5, 2002, Pages 735-740

  Peltola, K E ^a,b   Jaaskelainen S ^a   Heinonen, O J ^b,c   Falck, B ^a   Nanto Salonen K ^a   Heinanen K ^a   Simell, O ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b Paavo Nurmi Centre   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; ORNITHINE OXOACID AMINOTRANSFERASE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN LEVEL; CHILD; CLINICAL ARTICLE; EVOKED BRAIN STEM RESPONSE; EVOKED SOMATOSENSORY RESPONSE; FEMALE; HUMAN; HYPERORNITHINEMIA; MALE; MUSCLE ATROPHY; MUSCLE LEVEL; NEUROGRAPHY; PERCEPTIVE THRESHOLD; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETINA GYRATE ATROPHY; VISUAL IMPAIRMENT;

EID: 0037056368     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.59.5.735     Document Type: Article

References (38)

1. OMIM, Online Mendelian Inheritance in Man. 2001. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD).
2. Takki K, Simell O. Genetic aspects in gyrate atrophy of the choroid and retina with hyperornithinaemia. Br J Ophthalmol 1974;58:907-916.
3. Heinänen K, Näntö-Salonen K, Leino L, et al. Gyrate atrophy of the choroid and retina: lymphocyte ornithine-deltaaminotransferase activity in different mutations and carriers. Pediatr Res 1998;44:381-385.
4. Valle D, Simell O. The hyperornithinemias. In: Scriver CR, Sly WS, Childs, B, et al., eds. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001: 1857-1895.
5. Heinänen K, Näntö-Salonen K, Komu M, et al. Muscle creatine phosphate in gyrate atrophy of the choroid and retina with hyperornithinaemia- clues to pathogenesis. Eur J Clin Invest 1999;29:426-431.
6. Sipilä I, Simell O, Rapola J, Sainio K, Tuuteri L. Gyrate atrophy of the choroid and retina with hyperornithinemia: tubular aggregates and type 2 fiber atrophy in muscle. Neurology 1979;29:996-1005.
7. Sipilä I, Simell O, Arjomaa P. Gyrate atrophy of the choroid and retina with hyperornithinemia. Deficient formation of guanidinoacetic acid from arginine. J Clin Invest 1980;66: 684-687.
8. Kaiser-Kupfer MI, Ludwig IH, de Monasterio FM, Valle D, Krieger I. Gyrate atrophy of the choroid and retina. Early findings. Ophthalmology 1985;92:394-401.
9. Takki K. Gyrate atrophy of the choroid and retina associated with hyperornithinaemia. Br J Ophthalmol 1974;58:3-23.
10. Valtonen M, Näntö-Salonen K, Jääskelainen S, et al. Central nervous system involvement in gyrate atrophy of the choroid and retina with hyperornithinaemia. J Inherit Metab Dis 1999;22:855-866.
11. Peltola KE, Näntö-Salonen K, Heinonen OJ, et al. Ophthalmologic heterogeneity in subjects with gyrate atrophy of choroid and retina harboring the L402P mutation of ornithine aminotransferase. Ophthalmology 2001;108:721-729.
12. Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1988;11:21-32.
13. Stålberg E, Falck B. Clinical motor neurography. Methods Clin Neurophysiol 1993;4:61-80.
14. Falck B, Bischoff C, Stålberg E. Clinical sensory neurography with surface electrodes. Methods Clin Neurophysiol 1994;5:1-20.
15. Fruhstorfer H, Lindblom U, Schmidt WC. Method for quantitative estimation of thermal thresholds in patients. J Neurol Neurosurg Psychiatry 1976;39:1071-1075.
16. American Electroencephalographic Society. International guidelines for evoked potential recording. Guidelines on evoked potentials. J Clin Neurophysiol 1994;11:40-73.
17. Falck B, Andreassen S, Groth T, et al. The development of a multicenter database for reference values in clinical neurophysiology: principles and examples. Comput Programs Biomed 1992;34:145-162.
18. Andersen H, Stalberg E, Falck B. F-wave latency, the most sensitive nerve conduction parameter in patients with diabetes mellitus. Muscle Nerve 1997;20:1296-1302.
19. Bril V, Ellison R, Ngo M, Bergstrom B, Raynard D, Gin H. Electrophysiological monitoring in clinical trials. Roche Neuropathy Study Group. Muscle Nerve 1998;21:1368-1373.
20. Ackil AA, Shahani BT, Young RR, Rubin NE. Late response and sural conduction studies. Usefulness in patients with chronic renal failure. Arch Neurol 1981;38:482-485.
21. Wang T, Steel G, Milam AH, Valle D. Correction of ornithine accumulation prevents retinal degeneration in a mouse model of gyrate atrophy of the choroid and retina. Proc Natl Acad Sci USA 2000;97:1224-1229.
22. Sipilä I. Inhibition of arginine-glycine amidinotransferase by ornithine. A possible mechanism for the muscular and chorioretinal atrophies in gyrate atrophy of the choroid and retina with hyperornithinemia. Biochim Biophys Acta 1980;613:79-84.
23. Hiroi K, Yamamoto F, Honda Y. Effects of ornithine on the electroretinogram in cat retina. Invest Ophthalmol Vis Sci 1995;36:1732-1737.
24. Näntö-Salonen K, Komu M, Lundbom N, et al. Reduced brain creatine in gyrate atrophy of the choroid and retina with hyperornithinemia. Neurology 1999;53:303-307.
25. Stöckler S, Hanefeld F, Frahm J. Creatine replacement therapy in guanidinoacetate methyltransferase deficiency, a novel inborn error of metabolism. Lancet 1996;348:789-790.
26. Ganesan V, Johnson A, Connelly A, Eckhardt S, Surtees RA. Guanidinoacetate methyltransferase deficiency: new clinical features. Pediatr Neurol 1997;17:155-157.
27. Tarnopolsky MA, Parise G. Direct measurement of high-energy phosphate compounds in patients with neuromuscular disease. Muscle Nerve 1999;22:1228-1233.
28. Tarnopolsky MA, Beal MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol 2001;49:561-574.
29. Vannas-Sulonen K, Simell O, Sipilä, I. Gyrate atrophy of the choroid and retina. The ocular disease progresses in juvenile patients despite normal or near normal plasma ornithine concentration. Ophthalmology 1987;94:1428-1433.
30. Vannas-Sulonen K, Sipilä I, Vannas A, Simell O, Rapola J. Gyrate atrophy of the choroid and retina. A five-year follow-up of creatine supplementation. Ophthalmology 1985;92:1719-1727.
31. Kaiser-Kupfer MI, Caruso RC, Valle D. Gyrate atrophy of the choroid and retina. Long-term reduction of ornithine slows retinal degeneration. Arch Ophthalmol 1991;109:1539-1548.
32. Peltola K, Heinonen OJ, Näntö-Salonen K, Pulkki K, Simell O. Oral lysine feeding in gyrate atrophy with hyperornithinaemia-a pilot study. J Inherit Metab Dis 2000;23: 305-307.
33. Kaiser-Kupfer MI, de Monasterio F, Valle D, Walser M, Brusilow S. Visual results of a long-term trial of a low-arginine diet in gyrate atrophy of choroid and retina. Ophthalmology 1981;88:307-310.
34. Dechent P, Pouwels PJW, Wilken B, Hanefeld F, Frahm J. Increase of total creatine in human brain after oral supplementation of creatine-monohydrate. Am J Physiol 1999;277: P698-P704.
35. Holtzman D, Meyers R, O'Gorman E, et al. In vivo brain phosphocreatine and ATP regulation in mice fed a creatine analog. Am J Physiol 1997;272:C1567-C1577.
36. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999;5:347-350.
37. Braissant O, Henry H, Loup M, Eilers B, Bachmann C. Endogenous synthesis and transport of creatine in the rat brain: an in situ hybridization study. Brain Res Mol Brain Res 2001; 86:193-201.
38. Takki KK, Milton RC. The natural history of gyrate atrophy of the choroid and retina. Ophthalmology 1981;88:292-301.